Getting to the Heart of Alzheimer Disease.

Circ Res

From the College of Nursing (J.M.T., J.M.A., L.E.W.), The Ohio State University, Columbus.

Published: January 2019

AI Article Synopsis

  • Alzheimer disease (AD) is primarily recognized as a brain disorder characterized by specific brain changes, including Aβ plaques and tau tangles, which lead to symptoms like memory loss and confusion.
  • Research shows a significant relationship between cardiovascular issues (like heart failure and atrial fibrillation) and Alzheimer's, particularly how poor blood flow to the brain may contribute to neuronal damage.
  • New studies suggest that the protein deposits typically seen in AD are also found in the hearts of certain patients, indicating a broader systemic connection and prompting further exploration of how heart health may relate to Alzheimer's symptoms.

Article Abstract

In a somewhat narrow diagnostic lens, Alzheimer disease (AD) has been considered a brain-specific disease characterized by the presence of Aβ (β-amyloid) plaques and tau neural fibrillary tangles and neural inflammation; these pathologies lead to neuronal death and consequently clinical symptoms, such as memory loss, confusion, and impaired cognitive function. However, for decades, researchers have noticed a link between various cardiovascular abnormalities and AD-such as heart failure, coronary artery disease, atrial fibrillation, and vasculopathy. A considerable volume of work has pointed at this head to heart connection, focusing mainly on associations between cerebral hypoperfusion and neuronal degradation. However, new evidence of a possible systemic or metastatic profile to AD calls for further analysis of this connection. Aβ aggregations-biochemically and structurally akin to those found in the typical AD pathology-are now known to be present in the hearts of individuals with idiopathic dilated cardiomyopathy, as well as the hearts of patients with AD. These findings suggest a potential systemic profile of proteinopathies and a new hypothesis for the link between peripheral and central symptoms of heart failure and AD. Herein, we provide an overview of the cardiovascular links to Alzheimer disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319653PMC
http://dx.doi.org/10.1161/CIRCRESAHA.118.313563DOI Listing

Publication Analysis

Top Keywords

alzheimer disease
12
heart failure
8
disease
5
heart
4
heart alzheimer
4
disease narrow
4
narrow diagnostic
4
diagnostic lens
4
lens alzheimer
4
disease considered
4

Similar Publications

The development of multifunctional therapeutic agents is crucial for addressing complex diseases such as Alzheimer's disease. Herein, we report a ruthenium-rhenium (Ru-Re) complex that combines photodynamic therapy (PDT) and carbon monoxide (CO) generation capabilities. The Ru-Re complex shows promising photophysical property and significant therapeutic potential.

View Article and Find Full Text PDF

Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain.

Inflammopharmacology

December 2024

Department of Research and Development, First Floor, Molecules Biolabs Private Limited, Commercial Building Kinfra, 3/634Konoor Road, Muringur, Vadakkummuri, Koratty, Mukundapuram, Thrissur, Kerala, 680309, India.

Palmitoylethanolamide (PEA) is emerging as a promising therapeutic agent for neuropathic and other pain-related conditions. This naturally occurring fatty acid has drawn interest because of its ability to regulate pain and inflammation. Initially identified in food sources, PEA has been the subject of extensive research to elucidate its properties, efficacy, and clinical applications.

View Article and Find Full Text PDF

RASGEF1C as a novel prognostic biomarker for LUAD.

Discov Oncol

December 2024

Department of Thoracic Surgery, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New Area, Shanghai, China.

Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood.

View Article and Find Full Text PDF

A Self-Reinforced "Microglia Energy Modulator" for Synergistic Amyloid-β Clearance in Alzheimer's Disease Model.

Angew Chem Int Ed Engl

December 2024

Nanyang Technological University, School of Chemistry, Chemical Engineering and Biotechnology, 21 Nanyang Link, 637371, Singapore, SINGAPORE.

Microglial phagocytosis is a highly energy-consuming process that plays critical roles in clearing neurotoxic amyloid-β (Aβ) in Alzheimer's disease (AD). However, microglial metabolism is defective overall in AD, thereby undermining microglial phagocytic functions. Herein, we repurpose the existing antineoplastic drug lonidamine (LND) conjugated with hollow mesoporous Prussian blue (HMPB) as a "microglial energy modulator" (termed LND@HMPB-T7) for safe and synergistic Aβ clearance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!